• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

GSK tests Rotacaps inhaler versus Diskus for Advair

As GSK announced its 2011 results, which included sales declines for Advair (Seretide) in the US and Europe, and after the announcement that it plans to file a marketing application for its Relovair fluticasone furoate/vilanterol DPI despite disappointing data, Bloomberg took note of GSK’s recent study of a cheaper capsule-based inhaler for delivery of Advair (Seretide).

The 60-patient double-blind, double-dummy study is described on the clinicaltrials.gov website as “a comparative bioavailability study to compare the pharmacokinetics and pharmacodynamic effects of Fluticasone propionate and Salmeterol delivered in a capsule-based inhaler versus a multi-dose dry powder inhaler in patients with moderate asthma and in patients with moderate to severe COPD” and specifies that the inhalers involved are the Rotacaps and the Diskus.

Bloomberg notes that “A single-dose, capsule-based inhaler is less complex and less expensive than the Advair Diskus, and may be aimed at customers in emerging markets,” and “The experimental product may also be targeting possible generic versions of Advair, such as VR 315, which is being developed by Novartis AG (NOVN)’s Sandoz unit and Vectura Group Plc (VEC).”

Read GSk’s 2011 report.
Read the Bloomberg article.
Read the clinicaltrials.gov study description.

Share

published on February 9, 2012

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews